MB-dNPM1-TCR.1 in Relapsed/Refractory AML

Summary

The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A\*02:01 in patients with relapsed or refractory AML.

Timeline

Start

2024-08-01

Primary completion

2028-06

Completion

2028-06

Drugs

Indications